# A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

> **NCT00818662** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 390 (actual)

## Conditions studied

- Alzheimer´s Disease

## Interventions

- **BIOLOGICAL:** Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
- **BIOLOGICAL:** Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
- **BIOLOGICAL:** Placebo solution: Human Albumin 0.25% - 4 mL/kg
- **BIOLOGICAL:** Placebo solution: Human Albumin 0.25% - 2 mL/kg

## Key facts

- **NCT ID:** NCT00818662
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-19
- **Primary completion:** 2012-12-10
- **Final completion:** 2012-12-10
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2021-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818662, "A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00818662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*